Evaluate New Indications Before Committing Programs

Cross-verify target applicability and novelty before pursuing indication pivots or repurposing.

The Gap in Current Tools

Prediction models and internal teams do not capture the competitive landscape across new indications.
Lack of cross-program insight risks duplicate effort or wasted investment in programs that parallel activity has already invalidated.

Validate whether a proposed mechanism truly holds when translated to a new disease context — before clinical and commercial investment is committed.

Assess whether mechanisms are robust across indications.
Benchmark global research activity for competitive signals.
Quantify relative novelty and significance for internal and board-level evaluation.

Cross-institutional data, hypothesis infrastructure, and global knowledge signals are integrated without revealing individual sources.

Cross-hypothesis analysis integrates signals from related targets, adjacent pathways, and multi-dataset trends.
Supports decision-making with confidence even for high-risk indication pivots.

Commission your indication expansion report when a program decision point approaches.

Submit your program context and target indications.
Receive a formal, structured report highlighting mechanism validity, gaps, and competitive signals.

Explore adjacent validation types within your decision workflow.

View all Pharma validation reports for the full cluster overview and internal navigation.

Strategic Audit

Independent validation of target applicability and novelty across indications. Structured analysis for evidence-based indication strategy decisions.